BioRegenx, Inc.
BRGX
$0.0115
-$0.0005-4.17%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.26% | -32.08% | -24.98% | -14.98% | -48.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.26% | -32.08% | -24.98% | -14.98% | -48.91% |
| Cost of Revenue | -34.04% | -54.07% | -48.77% | -0.30% | -46.94% |
| Gross Profit | 5.67% | -14.63% | -15.69% | -21.46% | -49.71% |
| SG&A Expenses | -82.72% | 216.28% | -91.88% | -17.09% | 265.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.50% | 188.30% | -71.70% | 25.99% | 188.08% |
| Operating Income | 93.75% | -894.42% | 86.74% | -90.93% | -1,572.68% |
| Income Before Tax | 91.53% | -7,068.13% | 84.32% | -86.06% | -1,271.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 91.53% | -7,068.13% | 84.32% | -86.06% | -1,271.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 91.53% | -7,068.13% | 84.32% | -86.06% | -1,271.85% |
| EBIT | 93.75% | -894.42% | 86.74% | -90.93% | -1,572.68% |
| EBITDA | 93.01% | -627.04% | 110.02% | 68.79% | -1,310.01% |
| EPS Basic | 92.68% | -4,625.00% | 90.24% | -50.00% | -925.00% |
| Normalized Basic EPS | 92.31% | -600.00% | 88.00% | -40.00% | -1,200.00% |
| EPS Diluted | 92.68% | -4,625.00% | 90.24% | -50.00% | -925.00% |
| Normalized Diluted EPS | 92.31% | -600.00% | 88.00% | -40.00% | -1,200.00% |
| Average Basic Shares Outstanding | 24.67% | 39.44% | 53.80% | 25.15% | 24.01% |
| Average Diluted Shares Outstanding | 24.67% | 39.44% | 53.80% | 25.15% | 24.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |